For most of a decade, Lance Armstrong was the greatest comeback story in sport: a Texan who survived metastatic testicular cancer in 1996 and then won the Tour de France seven straight times, from 1999 to 2005. On August 24, 2012, the United States Anti-Doping Agency stripped all of it. He declined to contest the charges in arbitration, and USADA imposed a lifetime ban and disqualified every result he had recorded since August 1, 1998. On October 22, 2012, cycling’s governing body, the UCI, accepted the sanction and formally erased the seven titles. The Tour chose not to award them to anyone else. The record book for 1999 through 2005 now reads blank, which is its own kind of verdict.
The case against him was not a failed drug test. It was, in USADA’s published account, “the most sophisticated, professionalized and successful doping program that sport has ever seen” — a team-wide system on the US Postal Service squad built around EPO, blood transfusions, testosterone, cortisone, and human growth hormone, with saline infusions and careful timing used to stay ahead of the testers. USADA laid it out in October 2012 in a roughly 200-page Reasoned Decision backed by more than a thousand pages of evidence and the sworn testimony of 26 witnesses, including 15 riders and 11 of Armstrong’s own former teammates.
For years Armstrong’s defense had been four words long — I never failed a test — and in the narrow, technical sense it was almost true, which was precisely the problem the evidence exposed. He had not been caught by a vial of urine. He had been caught by the people who had doped alongside him. The man who had sued his accusers for defamation, and won settlements doing it, confessed the whole thing to Oprah Winfrey on television in January 2013.
The fall was not only reputational. Sponsors left in a single day; he stepped down from the cancer foundation he had built; and in 2018 he paid the US government $5 million to settle a whistleblower fraud suit brought by the teammate who had started the unravelling. What follows is how the most tested athlete in cycling ran the sport’s most elaborate doping program in plain sight, and how it finally came apart from the inside.
On September 24, 1988, Ben Johnson of Canada ran the men’s 100 metres final at the Seoul Olympics in 9.79 seconds, beat his great rival Carl Lewis, lowered his own world record, and stood at the top of the medal stand as, by acclamation, the fastest man who had ever lived. Three days later it was all gone. His post-race urine sample contained stanozolol, an anabolic steroid; the International Olympic Committee disqualified him, stripped the gold and the world record, and handed the title to Lewis. The verdict on the most famous nine seconds in track history was: stripped.
The mechanism was not subtle. Johnson had been on steroids for years — his own coach would later testify, under oath, that the program dated to 1981 — and the only genuine miscalculation was one of timing. Stanozolol is a synthetic steroid the body clears slowly, and Seoul’s anti-doping laboratory was looking for exactly that class of compound. A man who had spent the better part of a decade beating the system was undone by the elementary arithmetic of how long a drug stays in the body.
The fall was bottomless because the height had been absurd. Johnson was not merely an Olympic champion; he was a national hero in Canada and the headline act of a sport that had sold the Lewis-Johnson rivalry as a clean morality play. When the test came back, the Canadian government did not issue a statement and move on — it convened a judicial inquiry, the Dubin Commission, which sat for 91 days and turned the private machinery of elite-sprint doping inside out for a watching country.
Johnson got one chance to come back, and burned it. In January 1993, racing again after his suspension, he tested positive a second time, for excess testosterone. Under the governing body’s rules a second offence meant one outcome only, and he was banned from athletics for life. The man who had been the fastest alive for three days in 1988 spent the rest of his career as the sport’s permanent cautionary tale: the cheat who got caught, and then, given a second life, got caught again.
Marion Jones arrived at the Sydney 2000 Olympics promising to win five track-and-field medals and left having won exactly that — three gold (100m, 200m, 4x400m relay) and two bronze (long jump, 4x100m relay) — the most decorated American woman of the Games and, for the better part of a decade, one of the most celebrated athletes in the world. On December 12, 2007, the International Olympic Committee disqualified her from all five events and stripped every medal. The verdict on the haul was: stripped.
The substance at the centre of it was “the clear,” a designer steroid known as THG, supplied through the Bay Area Laboratory Co-operative — BALCO — that for years sat undetectable because no test had been designed to look for it. Jones’s coach, Trevor Graham, gave it to her; she would later say he told her it was flaxseed oil, a claim that is either the truth or the most convenient version of it, and which in the end mattered to no authority that ruled on her case.
What destroyed Marion Jones was not, in the strict sense, the doping. It was the lying about it. For years she denied any use of performance-enhancing drugs, sued an accuser, and built a public defence on indignant denial. When federal investigators questioned her in connection with the BALCO inquiry — and a separate check-fraud scheme — she lied to them, and lying to federal agents is itself a crime. On October 5, 2007, she pleaded guilty in a New York federal court to two counts of making false statements. On January 11, 2008, she was sentenced to six months in prison. The medals were a sporting matter; the cell was a criminal one.
The case is the clearest illustration in the doping canon of a particular lesson: that the cover-up is reliably more dangerous than the conduct it conceals. The doping cost Jones her medals, records, sponsors, and reputation — serious, but survivable. The denial, sustained to federal agents, cost her freedom. The record now reads that the woman who won five medals in Sydney won none of them, and went to prison for insisting otherwise.
Alberto Contador, the Spanish climber who had already won three Tours de France and was the dominant stage racer of his generation, was stripped of his 2010 Tour de France title and his 2011 Giro d’Italia victory after the Court of Arbitration for Sport ruled, on February 6, 2012, that he had committed a doping offence. The substance was clenbuterol, found in a urine sample on the second rest day of the 2010 Tour. The amount was vanishingly small — fifty picograms per millilitre, a level so low that the case became less about whether the drug was there than about how it had got there. CAS handed him a two-year ban backdated to January 25, 2011, and erased everything he had won in between.
The defence was a steak. Contador’s team argued that a friend had brought beef across the border from Spain, and that the meat had been contaminated with clenbuterol — a drug given illegally to cattle in some countries to build lean muscle. It was not an absurd story; meat contamination is real enough that WADA has formally warned athletes about it in China and Mexico. But under strict liability, an athlete is responsible for what is in his body regardless of how it arrived, and the only way out is to prove the innocent route on the balance of probabilities. Contador could not.
The institutional path was as much the story as the chemistry. After the positive was announced in September 2010, the matter went to the Spanish cycling federation, the RFEC, which first proposed a one-year ban and then, in early 2011, cleared Contador entirely. The Union Cycliste Internationale and the World Anti-Doping Agency each appealed that acquittal to CAS — the court that sits above national federations precisely so that a home body cannot have the final word on its own star. CAS overturned the clearance, the rare and telling feature of the case: an athlete acquitted at home, convicted on appeal.
CAS, notably, did not endorse the steak. Investigators found no clenbuterol in the traced beef, and the panel judged meat contamination very unlikely; it also rejected the prosecution’s theory of a blood transfusion as unproven. Its actual finding was a third option: that the most probable source was a contaminated food supplement. The verdict on record, then, is a two-year ban and two vacated Grand Tours, resting not on proof of how the drug entered Contador’s body but on his failure to prove it had entered innocently.
Rashid Ramzi, the Moroccan-born middle-distance runner who competed for Bahrain, won the 1500 metres at the 2008 Beijing Olympics and, on November 18, 2009 — some fifteen months later — was stripped of the gold by the International Olympic Committee for doping with CERA, a third-generation form of EPO. He had passed his doping controls at the Games. The samples were not flawed; the test had simply not yet been good enough to read them, and when it improved, the IOC went back and read them again. Kenya’s Asbel Kiprop was promoted to gold, New Zealand’s Nicholas Willis to silver, and France’s Mehdi Baala to bronze. Ramzi was the only champion of the Beijing Games caught in the re-analysis.
The substance was the case’s signature. CERA — continuous erythropoietin receptor activator, sold by Roche as Mircera under the generic name methoxy polyethylene glycol-epoetin beta — is an engineered descendant of recombinant EPO designed to last far longer in the body, with the longest half-life of any approved erythropoiesis-stimulating agent. That endurance is the point for a kidney patient, who can be dosed once or twice a month instead of several times a week. It is also, for an athlete trying to evade detection, a serious miscalculation: a molecule built to linger is a molecule that lingers in a stored sample, waiting to be found. CERA had been approved in Europe in August 2007 and by the US FDA in January 2008, and within months it was turning up at the 2008 Tour de France. By Beijing, the laboratories were closing the gap.
The mechanism that undid Ramzi was not a tip-off or a confession but the IOC’s policy of freezing Olympic samples and re-testing them when the science advances. The Beijing samples were collected in August 2008 and cleared at the time. In 2009, once a fully validated CERA assay existed, the IOC thawed a batch and ran it again. Five athletes failed the second look; Ramzi’s was the only gold among them. His B-sample was confirmed positive in July 2009, and the IOC ratified the disqualification that November.
What followed was comparatively quiet. Ramzi, who had been the first Bahraini to win an Olympic athletics title and one of the few men ever to take the 800m–1500m double at a World Championships, lost the medal and served a two-year ban. There was no career rehabilitation to forgive, because there was barely a career left. The case endures less for its drama than for what it proved about time: that the finish line is not the end of the contest, and that a clean result in 2008 was only ever provisional.